The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback